N@N

Isotechnika Pharma Inc. appoints Robert B. Huizinga as Vice President, Clinical Affairs

^{Published on 2011-08-23 06:41:01 - Market Wire}
 

EDMONTON, Aug. 23, 2011 /CNW/ - Isotechnika Pharma Inc. (TSX:ISA) is pleased to announce the appointment of Robert B. Huizinga to the role of Vice President, Clinical Affairs.  In this position, Mr. Huizinga will lead the development and execution of global clinical trial strategies for the Company's lead drug, voclosporin.  This position oversees the strategic planning phase through conducting and reporting of the trial results, including design and implementation of complex protocols, and training of site and internal staff in protocol specific procedures.

Mr. Huizinga has been with the Company since 2002, and most recently served as Senior Director, Clinical Affairs, focused on managing the global clinical development of voclosporin.  Before joining Isotechnika, Mr. Huizinga was a Nephrology and Transplantation nursing specialist with 14 years of clinical and research experience where he was involved in more than 60 clinical trials from Phase I through Phase IV.  He has acted as a consultant to nephrology and transplantation pharmaceutical companies, and has lectured extensively.  Over the years, Mr. Huizinga has established and nurtured close relationships in the nephrology and transplant communities, and has fostered strong connections with transplant investigators and clinical trial sites.

Mr. Huizinga has numerous articles published in leading medical journals, including the New England Journal of Medicine, Lancet, and the American Journal of Transplantation.  Mr. Huizinga is a member of many professional societies related to nephrology, transplantation and nursing, has served on many nephrology and transplantation committees, and is the founder of RenalPro, a moderated forum for renal professionals.  Mr. Huizinga holds a M.Sc. in Medicine (Epidemiology) from the University of Alberta, is a Registered Nurse, certified in Nephrology, and a member of Sigma Theta Tau (Honor Society of Nursing).

Dr. Robert Foster commented, "Mr. Huizinga has put tremendous effort into the clinical development of voclosporin.  The appointment of Mr. Huizinga to Vice President, Clinical Affairs underscores the importance of the preparation and execution of our Phase III renal transplant program.  His intimate experience with the clinical development of voclosporin, and his solid reputation in the nephrology and transplant communities make him an ideal candidate to oversee this process."

About Isotechnika Pharma Inc.

Isotechnika Pharma Inc. is a biopharmaceutical company focused on the discovery and development of immunomodulating therapeutics designed to offer key safety advantages over currently available treatments.  Its lead drug, voclosporin, is a calcineurin inhibitor, and is targeted at the estimated US$3.0 billion market for this class of immunosuppressants.  Isotechnika Pharma Inc. trades on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika Pharma can be found at [ www.isotechnika.com ] or [ www.sedar.com ].

We seek Safe Harbour.